118 related articles for article (PubMed ID: 29081073)
1. Urinary excretion of sphingomyelinase phosphodiesterase acid-like 3b in children with intractable nephrotic syndrome.
Watanabe S; Tsugawa K; Tsuruga K; Imaizumi T; Tanaka H
Pediatr Int; 2017 Oct; 59(10):1112-1115. PubMed ID: 29081073
[TBL] [Abstract][Full Text] [Related]
2. Podocyte sphingomyelin phosphodiesterase acid-like 3b decreases among children with idiopathic nephrotic syndrome.
Watanabe S; Hirono K; Aizawa T; Tsugawa K; Joh K; Imaizumi T; Tanaka H
Clin Exp Nephrol; 2021 Jan; 25(1):44-51. PubMed ID: 32946006
[TBL] [Abstract][Full Text] [Related]
3. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
Fornoni A; Sageshima J; Wei C; Merscher-Gomez S; Aguillon-Prada R; Jauregui AN; Li J; Mattiazzi A; Ciancio G; Chen L; Zilleruelo G; Abitbol C; Chandar J; Seeherunvong W; Ricordi C; Ikehata M; Rastaldi MP; Reiser J; Burke GW
Sci Transl Med; 2011 Jun; 3(85):85ra46. PubMed ID: 21632984
[TBL] [Abstract][Full Text] [Related]
4. The Importance of Sphingomyelin Phosphodiesterase Acid-Like 3b (SMPDL-3b) Levels in Kidney Biopsy Specimens of Children With Nephrotic Syndrome.
Kaya M; Girişgen İ; Yalçın N; Becerir T; Şenol H; Gülten G; Yüksel S
Fetal Pediatr Pathol; 2023 Dec; 42(6):936-949. PubMed ID: 37818552
[TBL] [Abstract][Full Text] [Related]
5. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes.
Takahashi Y; Ikezumi Y; Saitoh A
Nephrology (Carlton); 2017 Jan; 22(1):49-57. PubMed ID: 26833819
[TBL] [Abstract][Full Text] [Related]
6. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes.
Ahmad A; Mitrofanova A; Bielawski J; Yang Y; Marples B; Fornoni A; Zeidan YH
FASEB J; 2017 Feb; 31(2):771-780. PubMed ID: 27836988
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
Ahn YH; Kim SH; Han KH; Choi HJ; Cho H; Lee JW; Shin JI; Cho MH; Lee JH; Park YS; Ha IS; Cheong HI; Kim SY; Lee SJ; Kang HG
Medicine (Baltimore); 2018 Nov; 97(46):e13157. PubMed ID: 30431588
[TBL] [Abstract][Full Text] [Related]
8. Sphingomyelin Phosphodiesterase Acid-Like 3b is Essential for Toll-Like Receptor 3 Signaling in Human Podocytes.
Watanabe S; Hidenori U; Hashimoto S; Riko S; Aizawa T; Tsugawa K; Imaizumi T; Tanaka H
J Membr Biol; 2022 Feb; 255(1):117-122. PubMed ID: 34739556
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of rituximab therapy against intractable steroid-resistant nephrotic syndrome.
Nakagawa T; Shiratori A; Kawaba Y; Kanda K; Tanaka R
Pediatr Int; 2016 Oct; 58(10):1003-1008. PubMed ID: 26865241
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
Van Horebeek I; Knops N; Van Dyck M; Levtchenko E; Mekahli D
Acta Clin Belg; 2017 Jun; 72(3):147-155. PubMed ID: 27409338
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome.
Counsilman CE; Jol-van der Zijde CM; Stevens J; Cransberg K; Bredius RG; Sukhai RN
Pediatr Nephrol; 2015 Aug; 30(8):1367-70. PubMed ID: 26054711
[TBL] [Abstract][Full Text] [Related]
12. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?
Delbet JD; Leclerc G; Ulinski T
Pediatr Nephrol; 2019 Mar; 34(3):529-532. PubMed ID: 30542932
[TBL] [Abstract][Full Text] [Related]
14. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.
Fujinaga S; Sakuraya K; Yamada A; Urushihara Y; Ohtomo Y; Shimizu T
Pediatr Nephrol; 2015 Apr; 30(4):687-91. PubMed ID: 25576066
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
[TBL] [Abstract][Full Text] [Related]
16. Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome.
Iorember F; Aviles D; Kallash M; Bamgbola O
Pediatr Nephrol; 2018 Feb; 33(2):261-267. PubMed ID: 28864927
[TBL] [Abstract][Full Text] [Related]
17. Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation.
Tasaki M; Shimizu A; Hanekamp I; Torabi R; Villani V; Yamada K
J Am Soc Nephrol; 2014 Apr; 25(4):737-44. PubMed ID: 24459229
[TBL] [Abstract][Full Text] [Related]
18. B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.
Colucci M; Carsetti R; Cascioli S; Casiraghi F; Perna A; Ravà L; Ruggiero B; Emma F; Vivarelli M
J Am Soc Nephrol; 2016 Jun; 27(6):1811-22. PubMed ID: 26567244
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome.
Mishra OP; Kumar R; Narayan G; Srivastava P; Abhinay A; Prasad R; Singh A; Batra VV
Pediatr Nephrol; 2017 Aug; 32(8):1355-1361. PubMed ID: 28210837
[TBL] [Abstract][Full Text] [Related]
20. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.
Kisner T; Burst V; Teschner S; Benzing T; Kurschat CE
Nephron Clin Pract; 2012; 120(2):c79-85. PubMed ID: 22286071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
